Advancements in Metastatic Triple-Negative Breast Cancer: Treatment Discussions and Managed Care Considerations
Tuesday, Nov. 10, 2020, 10-11:30am ET
Provided by Pharmacy Times Continuing Education.
This activity is supported by educational grants from Eisai, Inc. and Genentech, a member of the Roche Group.
Continuing education credit available for pharmacists.
Triple-negative breast cancer (TNBC) is considered to be more aggressive and have a poorer prognosis than other types of breast cancer. TNBC tests negative for estrogen and progesterone receptors as well as HER2 overexpression, and therefore does not respond to hormonal or traditional targeted therapies. Chemotherapy is the foundation of treatment for TNBC, but efficacy, toxicity, and administration of medications must be factored into choice of therapy. Expanding treatment options for TNBC include targeted therapies based on tumor expression and inherited mutations. The aggressive course of metastatic TNBC is associated with high all-cause and cancer-related hospitalizations and total costs, placing a significant economic burden on both patients and payers. To overcome these challenges in the management of patients with TNBC, managed care professionals must be familiar with guideline recommendations and prepared to evaluate emerging therapies to provide value-based, cost-efficient care for patients.
Pharmacy Times Continuing Education